# MariTide

An antibody that blocks the GIP receptor, carrying two peptides that switch on GLP-1. The draw is a dose once a month, possibly less often.

Also called: Maridebart cafraglutide, AMG 133
Source page: https://peplogue.com/peptides/maritide/
Updated: 2026-10-22. Not medical advice.

## How it works

- Where it acts: It blocks GIP receptors with an antibody, while its two attached peptides switch on GLP-1 receptors.
- What it changes: Lower appetite. The antibody lasts for weeks, which is what allows a monthly dose.
- What people notice: Up to about 20% weight loss over a year in phase 2. Nausea and vomiting, mostly after the first dose.

## What the evidence shows

- **Weight loss in obesity**: Supported. Up to about 20% average loss at one year in phase 2. In the second year most people kept the loss on lower monthly or quarterly doses.

## Side effects and risks

- common: Nausea and vomiting, strongest after the first doses.
- unknown: Longer-term safety is not known.

Who should avoid it: Anyone outside a clinical trial.

## How it has been given in trials

Injection under the skin once a month. Eight-weekly and quarterly maintenance doses are being tested. There is no approved dose.

## Legal status

- United States: undefined
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**How often is MariTide given?**

Once a month as an injection under the skin in trials. Eight-weekly and quarterly maintenance doses are being tested.

**How much weight loss did MariTide give?**

Up to about 20% average loss at one year in phase 2. In the second year most people kept the loss on lower monthly or quarterly doses.

**How does MariTide work?**

It is an antibody that blocks the GIP receptor, carrying two attached peptides that switch on GLP-1 receptors. The antibody lasts for weeks, which allows a monthly dose.

**What are the side effects of MariTide?**

Nausea and vomiting, strongest after the first doses. Longer-term safety is not known.

**Is MariTide approved?**

No. The phase 3 program, MARITIME, is under way, and there is no approved dose.

## Sources

- Amgen: second-quarter 2026 results: https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000124/amgn-20260630earningsrelea.htm
- Amgen: fourth-quarter 2025 results: https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20251231earningsrelea.htm